Innate Pharma prices private placement of new shares at EUR 1.7 each

• Innate Pharma launched a capital increase without preferential rights, issuing new ordinary shares at EUR 1.7 each.
• U.S. tranche structured as a private placement to Rule 144A QIBs, relying on the Securities Act Section 4(a)(2) exemption.
• Closing set for Aug. 18, 2026 at 8:30 a.m. CET, with investor cash due in euros by wire.
• Shares to be delivered in bearer form through Stifel as centralizing agent, with Société Générale Securities Services as registrar.
• New shares expected to be listed on Euronext Paris on the closing date, subject to official issuance notice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-057935), on August 19, 2026, and is solely responsible for the information contained therein.